This week, in a conversation with Becker’s Healthcare, Dr. Andrew Hecht (MD, Mt. Sinai Hospital, New York City) named “annular repair and the field of disc biology” one of the next big trends in spine. Barricaid is designed to close large annular holes, thereby reducing reherniation rates in patients at higher risk. Thank you, Dr. Hecht, for addressing this important health issue, touching 1 million discectomy patients worldwide each year.
Barricaid demonstrates Intrinsic Therapeutics’ full commitment to optimizing outcomes in disc surgery. In January, the company hosted the first annual Disc Collective Meeting in New York City, NY. This meeting brought together leading surgeons and researchers to discuss how we can do better in optimizing outcomes in disc surgery, whereas the disc represents an integral part of the integrity and function of the spine.
Read the full article here: https://bit.ly/2I66Xfk